Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors
To learn if MEK162 (the study drug) is safe and has beneficial effects in people who have different types of cancer with pre-identified RAS/RAF/MEK mutations.
Select solid tumors and hematologic malignancies with RAF/RAS/MEK tumor activations
1. Male or female of at least 18 years of age.
2. Diagnosis of select solid tumor (except pancreatic, biliary, colorectal, low grade serous ovarian, and melanoma) or hematologic malignancy.
3. Pre-identified RAF, RAS, NF1, or MEK mutation.
4. Received at least one prior treatment for recurrent, metaastatic, and/or locally advanced disease.
5. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression or development of unacceptable side effects
Knight Clinical Trials Information Line